[{"address1": "No. 5, Xingdao Ring Road North", "address2": "International Bio Island", "city": "Guangzhou", "zip": "510005", "country": "China", "phone": "86 20 3403 7871", "website": "https://www.brbiotech.com", "industry": "Diagnostics & Research", "industryKey": "diagnostics-research", "industryDisp": "Diagnostics & Research", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China. It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. The company also provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients, as well as Magnis BR-customized version of its principal products. In addition, it offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. The company was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.", "fullTimeEmployees": 786, "companyOfficers": [{"maxAge": 1, "name": "Mr. Yusheng  Han", "age": 44, "title": "Founder, Chairman & CEO", "yearBorn": 1979, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jinxiang  Li", "age": 38, "title": "CFO, Compliance Officer & Director", "yearBorn": 1985, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Zhihong  Zhang", "age": 47, "title": "CTO & Director", "yearBorn": 1976, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Hao  Liu", "age": 49, "title": "Senior Advisor", "yearBorn": 1974, "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 4.75, "open": 4.96, "dayLow": 4.52, "dayHigh": 5.099, "regularMarketPreviousClose": 4.75, "regularMarketOpen": 4.96, "regularMarketDayLow": 4.52, "regularMarketDayHigh": 5.099, "beta": 0.15, "forwardPE": -8.105517, "volume": 13921, "regularMarketVolume": 13921, "averageVolume": 5095, "averageVolume10days": 7020, "averageDailyVolume10Day": 7020, "bid": 3.52, "ask": 5.95, "bidSize": 200, "askSize": 200, "marketCap": 48228200, "fiftyTwoWeekLow": 4.52, "fiftyTwoWeekHigh": 13.2, "priceToSalesTrailing12Months": 0.09460089, "fiftyDayAverage": 6.35094, "twoHundredDayAverage": 7.64301, "currency": "USD", "enterpriseValue": 62702372, "profitMargins": -1.11176, "floatShares": 55769520, "sharesOutstanding": 8526240, "sharesShort": 41852, "sharesShortPriorMonth": 41423, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0039, "heldPercentInsiders": 0.00039, "heldPercentInstitutions": 0.61753, "shortRatio": 10.8, "impliedSharesOutstanding": 102587000, "bookValue": 66.069, "priceToBook": 0.07115591, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -566780992, "trailingEps": -7.77, "forwardEps": -0.58, "lastSplitFactor": "1:10", "lastSplitDate": 1715731200, "enterpriseToRevenue": 0.123, "enterpriseToEbitda": -0.141, "52WeekChange": -0.61382115, "SandP52WeekChange": 0.24014747, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "BNR", "underlyingSymbol": "BNR", "shortName": "Burning Rock Biotech Limited", "longName": "Burning Rock Biotech Limited", "firstTradeDateEpochUtc": 1591968600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "20b4973b-d557-358c-9cbd-72e612a3f307", "messageBoardId": "finmb_309457193", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.7012, "targetHighPrice": 4.03, "targetLowPrice": 4.03, "targetMeanPrice": 4.03, "targetMedianPrice": 4.03, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 532542016, "totalCashPerShare": 5.191, "ebitda": -445377504, "totalDebt": 107910000, "quickRatio": 2.72, "currentRatio": 3.105, "totalRevenue": 509807008, "debtToEquity": 15.92, "revenuePerShare": 49.754, "returnOnAssets": -0.30913, "returnOnEquity": -0.68891, "freeCashflow": 7705250, "operatingCashflow": -144480992, "revenueGrowth": -0.073, "grossMargins": 0.67705, "ebitdaMargins": -0.87362, "operatingMargins": -0.82058, "financialCurrency": "CNY", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]